Showing 1141-1150 of 3020 results for "".
- Zydus Lifesciences Scores FDA Nod for Generic Acne Drughttps://practicaldermatology.com/news/zydus-lifesciences-scores-fda-nod-for-generic-acne-drug/2461791/The U.S. Food and Drug Administration (FDA) has given its nod to Zydus Lifesciences’ generic antibiotic minocycline hydrochloride extended-release tablets for the treatment of moderate to severe acne in 55 mg, 65 mg, and 115 mg doses, the Company reports. Minocycline hyd
- Gentle Cleansers Kill Viruses as Effectively as Harsh Soapshttps://practicaldermatology.com/news/gentle-cleansers-kill-viruses-as-effectively-as-harsh-soaps/2461780/Gentle cleansers are just as effective in killing viruses – including coronavirus - as harsh soaps, a new study out University of Sheffield experts has found. Scientists from the University of Sheffield’s Sh
- And the Winners Are…Botox Cosmetic Announces the Winners of the IFundWomen Grant Programhttps://practicaldermatology.com/news/and-the-winners-arebotox-cosmetic-announces-the-winners-of-the-ifundwomen-grant-program/2461779/Twenty female entrepreneurs will receive funding and mentorship through Allergan’s BOTOX Cosmetic and IFundWomen grant program. "There were so many remarkable applications that featured thoughtful business solutions," says Carrie Strom, President, Global Aller
- Dove, Gracie's Corner Join Forces to Educate Families on the CROWN Movementhttps://practicaldermatology.com/news/dove-gracies-corner-join-forces-to-educate-families-on-the-crown-movement/2461777/Dove is joining forces with "Gracie's Corner," a children's YouTube series, to celebrate the beauty of natural hair and help educate families about the need to Create a Respectful and Open Wo
- News You Can Use: SID Announces New Research Grant Program Focusing on Type 2 Inflammationhttps://practicaldermatology.com/news/news-you-can-use-sid-announces-new-research-grant-program-focusing-on-type-2-inflammation/2461767/The Society for Investigative Dermatology’s (SID) new research grant program, The SID Type 2 Inflammation Innovation Awards, is open now and the deadline is August 31, 2023
- Sol-Gel, Searchlight Pharma Partner to Commercialize TWYNEO and EPSOLAY in Canadahttps://practicaldermatology.com/news/sol-gel-searchlight-pharma-partner-to-commercialize-twyneo-and-epsolay-in-canada/2461764/Israel’s Sol-Gel Technologies, Ltd. and Searchlight Pharma Inc. have signed exclusive license agreements for TWYNEO and EPSOLAY for the Canadian market. Both products recently launched in the U.S., and Searchlight is to commercialize in Canada over a fifteen-year term that i
- Can Softening Stem Cells Coax Hair Growth in Aging Hair? Maybehttps://practicaldermatology.com/news/can-softening-stem-cells-coax-hair-growth-in-aging-hair/2461761/Hair follicle stem cells get stiff with age, making it harder for them to grow hair, but if the hair follicle’s stem cells are softened, they are more likely to produce hair, new research suggests. In a study in mice
- FDA Nod for Galderma's Restylane Eyelighthttps://practicaldermatology.com/news/fda-nod-for-galdermas-restylane-eyelight/2461760/The U.S. Food and Drug Administration (FDA) approved Restylane Eyelight, a hyaluronic acid (HA) dermal filler for the correction of undereye hollowing, in adults over the age of 21. Restylane Eyelight is formulated with NASHA Technology, which has a firm gel te
- TWi Biotechnology, Yale University Seek Participants With GA for Phase 1 trial of a Topical JAK Inhibitorhttps://practicaldermatology.com/news/twi-biotechnology-yale-university-seek-participants-with-ga-for-phase-1-trial-of-a-topical-jak-inhibitor/2461757/TWi Biotechnology (TWiB) is seeking participants for a Phase 1 clinical trial of a topical gel form of tofacitinib for the treatment of granuloma annulare (GA). Individuals with GA or friends and family members can find study information at:
- Scientists Identify Genomic Cause and Potential Treatment for Disabling Pansclerotic Morpheahttps://practicaldermatology.com/news/scientists-identify-genomic-cause-and-potential-treatment-for-disabling-pansclerotic-morphea/2461756/Researchers have identified genomic variants that cause disabling pansclerotic morphea and have found a potential treatment. People with the disorder have an overactive version of a protein called STAT4, which regulates inflammation and wound healing. The work also identified a drug tha